Article Details

Zerlasiran by Silence Therapeutics for Atherosclerosis: Likelihood of Approval

Retrieved on: 2024-02-19 17:59:55

Tags for this article:

Click the tags to see associated articles and topics

Zerlasiran by Silence Therapeutics for Atherosclerosis: Likelihood of Approval. View article details on hiswai:

Summary

The article discusses Zerlasiran, a siRNA-based drug by Silence Therapeutics for atherosclerosis, highlighting its Phase II success rate and approval likelihood using business intelligence from GlobalData related to the pharmaceutical industry.

Article found on: www.pharmaceutical-technology.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up